Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The effect of vericiguat, a novel oral soluble guanylate cyclase stimulator, in patients with heart failure and reduced ejection fraction who had recently been hospitalized or had received intravenous diuretic therapy is unclear. METHODS: In this phase 3, randomized, double-blind, placebo-controlled trial, we assigned 5 050 patients with chronic heart failure (New York Heart Association class II, III, or IV) and an ejection fraction of less than 45% to receive vericiguat (target dose 10 mg once daily) or placebo, in addition to guideline-based medical therapy.The primary outcome was a composite of death from cardiovascular causes or first hospitalization for heart failure. RESULTS: Over a median of 10.8 months, a primary-outcome event occurred in 897 of 2 526 patients (35.5%) in the vericiguat group and in 972 of 2 524 patients (38.5%) in the placebo group (p = 0.02). A total of 691 patients (27.4%) in the vericiguat group and 747 patients (29.6%) in the placebo group were hospitalized for heart failure. Death from cardiovascular causes occurred in 414 patients (16.4%) in the vericiguat group and in 441 patients (17.5%) in the placebo group. The composite endpoint of death from any cause or hospitalization for heart failure occurred in 957 patients (37.9%) in the vericiguat group and in 1 032 patients (40.9%) in the placebo group (p = 0.02). Symptomatic hypotension occurred in 9.1% of the patients in the vericiguat group and in 7.9% of the patients in the placebo group (p = 0.12), syncope occurred in 4.0% of the patients in the vericiguat group and in 3.5% of the patients in the placebo group (p = 0.30). CONCLUSION: Among patients with high-risk heart failure, the incidence of death from cardiovascular causes or hospitalization for heart failure was lower among those who received vericiguat than those who received placebo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“From a safety perspective, there was more hypotension in the vericiguat group but this did not contribute to renal dysfunction, despite the relatively low eGFR cutoff for enrollment.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [71]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Of note, the secondary end point of total HHF was also decreased in the vericiguat group (HR, 0.91 [95% CI 0.84-0.99]; P = 0.023).”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [71]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The primary combined end point of CV death or first HHF was significantly lower (HR, 0.90 [95% CI 0.82-0.98]; P = 0.019) in the vericiguat group and this was driven primarily by a reduction in hospitalization rather than CV death.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [71]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
Benjamin, E. J., Muntner, P., Alonso, A., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Das, S. R., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000659 · Cited by 9,036
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Self-citationAngiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957
Cox’s regression model for counting processes: A large sample study
Andersen, P. K., & Gill, R. D. (1982) · The Annals of Statistics · doi:10.1214/aos/1176345976 · Cited by 4,419
Heidenreich, P. A., Albert, N. M., Allen, L. A., Bluemke, D. A., Butler, J., Fonarow, G. C., Ikonomidis, J. S., Khavjou, O., Konstam, M. A., Maddox, T. M., et al. (2013) · Circulation: Heart Failure · doi:10.1161/hhf.0b013e318291329a · Cited by 2,804
Self-citationSoluble Guanylate Cyclase as an Emerging Therapeutic Target in Cardiopulmonary Disease
Stasch, J.-P., Pacher, P., & Evgenov, O. V. (2011) · Circulation · doi:10.1161/circulationaha.110.981738 · Cited by 601
Ruppar, T. M., Cooper, P. S., Mehr, D. R., Delgado, J. M., & Dunbar‐Jacob, J. M. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.002606 · Cited by 415
Gheorghiade, M., Greene, S. J., Butler, J., Filippatos, G., Lam, C. S. P., Maggioni, A. P., Ponikowski, P., Shah, S. J., Solomon, S. D., Kraigher-Krainer, E., et al. (2015) · JAMA · doi:10.1001/jama.2015.15734 · Cited by 397
Self-citationClinical Course of Patients With Worsening Heart Failure With Reduced Ejection Fraction
Butler, J., Yang, M., Manzi, M. A., Hess, G. P., Patel, M. J., Rhodes, T., & Givertz, M. M. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.049 · Cited by 245
Self-citationArmstrong, P. W., Roessig, L., Patel, M. J., Anstrom, K. J., Butler, J., Voors, A. A., Lam, C. S. P., Ponikowski, P., Temple, T., Pieske, B., et al. (2018) · JACC: Heart Failure · doi:10.1016/j.jchf.2017.08.013 · Cited by 208
Self-citation
Cited by
2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab368 · Cited by 13,344
Self-citation2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Benetos, A., Biffi, A., Boavida, J.-M., Capodanno, D., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab484 · Cited by 6,485
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001063 · Cited by 4,922
Self-citation2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.012 · Cited by 2,862
Self-citationAuthors/Task Force Members:, McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2333 · Cited by 2,171
Self-citationBozkurt, B., Coats, A. J. S., Tsutsui, H., Abdelhamid, C. M., Adamopoulos, S., Albert, N., Anker, S. D., Atherton, J., Böhm, M., Butler, J., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2115 · Cited by 1,665
Self-citationUniversal Definition and Classification of Heart Failure
Bozkurt, B., Coats, A. J., Tsutsui, H., Abdelhamid, M., Adamopoulos, S., Albert, N., Anker, S. D., Atherton, J., Böhm, M., Butler, J., et al. (2021) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2021.01.022 · Cited by 995
Self-citationMaddox, T. M., Januzzi, J. L., Allen, L. A., Breathett, K., Butler, J., Davis, L. L., Fonarow, G. C., Ibrahim, N. E., Lindenfeld, J., Masoudi, F. A., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.022 · Cited by 842
Self-citationNitric oxide signaling in health and disease
Lundberg, J. O., & Weitzberg, E. (2022) · Cell · doi:10.1016/j.cell.2022.06.010 · Cited by 826
Sex differences in heart failure
Lam, C. S. P., Arnott, C., Beale, A. L., Chandramouli, C., Hilfiker-Kleiner, D., Kaye, D. M., Ky, B., Santema, B. T., Sliwa, K., & Voors, A. A. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz835 · Cited by 802
Self-citationHeart Failure With Reduced Ejection Fraction: A Review
Murphy, S. P., Ibrahim, N. E., & Januzzi, J. L. (2020) · JAMA · doi:10.1001/jama.2020.10262 · Cited by 769
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Benetos, A., Biffi, A., Boavida, J.-M., Capodanno, D., et al. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab154 · Cited by 542
Heart failure with mid-range or mildly reduced ejection fraction
Savarese, G., Stolfo, D., Sinagra, G., & Lund, L. H. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00605-5 · Cited by 476
Pop-Busui, R., Januzzi, J. L., Bruemmer, D., Butalia, S., Green, J. B., Horton, W. B., Knight, C., Levi, M., Rasouli, N., & Richardson, C. R. (2022) · Diabetes Care · doi:10.2337/dci22-0014 · Cited by 399
Tromp, J., Ouwerkerk, W., van Veldhuisen, D. J., Hillege, H. L., Richards, A. M., van der Meer, P., Anand, I. S., Lam, C. S. P., & Voors, A. A. (2022) · JACC: Heart Failure · doi:10.1016/j.jchf.2021.09.004 · Cited by 401
Self-citationMaddox, T. M., Januzzi, J. L., Allen, L. A., Breathett, K., Brouse, S., Butler, J., Davis, L. L., Fonarow, G. C., Ibrahim, N. E., Lindenfeld, J., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.12.024 · Cited by 362
Self-citationWorsening Heart Failure: Nomenclature, Epidemiology, and Future Directions
Greene, S. J., Bauersachs, J., Brugts, J. J., Ezekowitz, J. A., Lam, C. S. P., Lund, L. H., Ponikowski, P., Voors, A. A., Zannad, F., Zieroth, S., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.11.023 · Cited by 303
Self-citationArmstrong, P. W., Lam, C. S. P., Anstrom, K. J., Ezekowitz, J., Hernandez, A. F., O’Connor, C. M., Pieske, B., Ponikowski, P., Shah, S. J., Solomon, S. D., et al. (2020) · JAMA · doi:10.1001/jama.2020.15922 · Cited by 293
Self-citationMcDonald, M., Virani, S., Chan, M., Ducharme, A., Ezekowitz, J. A., Giannetti, N., Heckman, G. A., Howlett, J. G., Koshman, S. L., Lepage, S., et al. (2021) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2021.01.017 · Cited by 287
“In the Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) trial the efficacy and safety of vericiguat compared with standard of care was evaluated in patients with advanced functional symptoms, an LVEF < 45% and a worsening HF event characterized by HHF or elevated natriur…”
BackgroundMethodSelf-citationEndothelial Dysfunction in Chronic Kidney Disease, from Biology to Clinical Outcomes: A 2020 Update
Roumeliotis, S., Mallamaci, F., & Zoccali, C. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9082359 · Cited by 284
Nitric oxide signalling in kidney regulation and cardiometabolic health
Carlström, M. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-021-00429-z · Cited by 252
Peled, Y., Ducharme, A., Kittleson, M., Bansal, N., Stehlik, J., Amdani, S., Saeed, D., Cheng, R., Clarke, B., Dobbels, F., et al. (2024) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2024.05.010 · Cited by 240
Butler, J., Anker, S. D., Lund, L. H., Coats, A. J. S., Filippatos, G., Siddiqi, T. J., Friede, T., Fabien, V., Kosiborod, M., Metra, M., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac401 · Cited by 231
“18 In this regard, it is important to note that in the DIAMOND trial, 84.6% of the patients at the end of run-in phase were able to achieve ≥ 50% of target dose of the combination RAASi therapy and 97% were able to take the triple therapy at some dose.”
BackgroundInfluentialSelf-citationBeldhuis, I. E., Lam, C. S. P., Testani, J. M., Voors, A. A., Van Spall, H. G. C., ter Maaten, J. M., & Damman, K. (2022) · Circulation · doi:10.1161/circulationaha.121.052792 · Cited by 216
Self-citationPathophysiology and Therapeutic Approaches to Acute Decompensated Heart Failure
Njoroge, J. N., & Teerlink, J. R. (2021) · Circulation Research · doi:10.1161/circresaha.121.318186 · Cited by 214
Metra, M., Tomasoni, D., Adamo, M., Bayes-Genis, A., Filippatos, G., Abdelhamid, M., Adamopoulos, S., Anker, S. D., Antohi, L., Böhm, M., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2874 · Cited by 208
Self-citationJCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure
Kitai, T., Kohsaka, S., Kato, T., Kato, E., Sato, K., Teramoto, K., Yaku, H., Akiyama, E., Ando, M., Izumi, C., et al. (2025) · Circulation Journal · doi:10.1253/circj.cj-25-0002 · Cited by 191
Mentz, R. J., Anstrom, K. J., Eisenstein, E. L., Sapp, S., Greene, S. J., Morgan, S., Testani, J. M., Harrington, A. H., Sachdev, V., Ketema, F., et al. (2023) · JAMA · doi:10.1001/jama.2022.23924 · Cited by 189
Self-citationJCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure
Tsutsui, H., Ide, T., Ito, H., Kihara, Y., Kinugawa, K., Kinugawa, S., Makaya, M., Murohara, T., Node, K., Saito, Y., et al. (2021) · Circulation Journal · doi:10.1253/circj.cj-21-0431 · Cited by 183
Sex Differences in Heart Failure
Lala, A., TAYAL, U., HAMO, C. E., YOUMANS, Q., AL-KHATIB, S. M., BOZKURT, B., DAVIS, M. B., JANUZZI, J., MENTZ, R., SAUER, A., et al. (2022) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2021.10.006 · Cited by 179
Therapeutic targets for cardiac fibrosis: from old school to next-gen
Travers, J. G., Tharp, C. A., Rubino, M., & McKinsey, T. A. (2022) · Journal of Clinical Investigation · doi:10.1172/jci148554 · Cited by 173
“In line with this protective mechanism, vericiguat (76), which elevates cGMP by functioning as a soluble guanylate cyclase (sGC) stimulator, was recently approved for the treatment of HFrEF.”
BackgroundEpidemiology, Pathophysiology, Diagnosis and Treatment of Heart Failure in Diabetes
Park, J. J. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0282 · Cited by 171
“In VerICiguaT GlObal Study in Subjects With Heart Failure With Reduced EjectIon FrAction (VICTORIA) study [87], vericiguat, an oral soluble guanylate cyclase stimulator that improves the cardiac contractility, reduced the composite of allcause deaths and HHF by 10% (hazard ratio, 0.”
MethodAllen, L. A., Venechuk, G., McIlvennan, C. K., Page, R. L., Knoepke, C. E., Helmkamp, L. J., Khazanie, P., Peterson, P. N., Pierce, K., Harger, G., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.051863 · Cited by 170
3-Year Outcomes of Transcatheter Mitral Valve Repair in Patients With Heart Failure
Mack, M. J., Lindenfeld, J., Abraham, W. T., Kar, S., Lim, D. S., Mishell, J. M., Whisenant, B. K., Grayburn, P. A., Rinaldi, M. J., Kapadia, S. R., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.12.047 · Cited by 165
Packer, M., & McMurray, J. J. V. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2149 · Cited by 160
JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure
Tsutsui, H., Ide, T., Ito, H., Kihara, Y., Kinugawa, K., Kinugawa, S., Makaya, M., Murohara, T., Node, K., Saito, Y., et al. (2021) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2021.04.023 · Cited by 158
Müllens, W., Martens, P., Testani, J. M., Tang, W. H. W., Skouri, H. N., Verbrugge, F. H., Fudim, M., Iacoviello, M., Franke, J., Flammer, A. J., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2471 · Cited by 164
Yurista, S. R., Matsuura, T. R., Silljé, H. H. W., Nijholt, K. T., McDaid, K. S., Shewale, S. V., Leone, T. C., Newman, J. C., Verdin, E. M., van Veldhuisen, D. J., et al. (2020) · Circulation Heart Failure · doi:10.1161/circheartfailure.120.007684 · Cited by 146
Pugliese, N. R., Pellicori, P., Filidei, F., De Biase, N., Maffia, P., Guzik, T. J., Masi, S., Taddei, S., & Cleland, J. G. F. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvac133 · Cited by 144
“HFrEF, the VICTORIA trial suggested a reduction in morbidity and mortality, except in those with a very high NT-proBNP (>5314 ng/L) who appeared to be harmed.(123) However, for patients with HFpEF (SOCRATES-PRESERVED, n = 477 and VITALITY-HFpEF, n = 789), vericiguat failed to reduce plasma NT-proBNP concentrations, le…”
BackgroundN-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes
Ezekowitz, J. A., O’Connor, C. M., Troughton, R. W., Alemayehu, W. G., Westerhout, C. M., Voors, A. A., Butler, J., Lam, C. S. P., Ponikowski, P., Emdin, M., et al. (2020) · JACC: Heart Failure · doi:10.1016/j.jchf.2020.08.008 · Cited by 146
Self-citationRan, J., Zhou, P., Wang, J., Zhao, X., Huang, Y., Zhou, Q., Zhai, M., & Zhang, Y. (2025) · Biomarker Research · doi:10.1186/s40364-025-00728-8 · Cited by 187
“Our findings on HF burden trends align with previous related studies, and future analyses using alternative data sources may provide further validation of these observations(4).”
Guía ESC 2021 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O. D., et al. (2022) · Revista Española de Cardiología · doi:10.1016/j.recesp.2021.11.027 · Cited by 177
Self-citationMichos, E. D., Reddy, T. K., Gulati, M., Brewer, L. C., Bond, R. M., Velarde, G. P., Bailey, A. L., Echols, M. R., Nasser, S. A., Bays, H. E., et al. (2021) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2021.100250 · Cited by 126
Atualização de Tópicos Emergentes da Diretriz Brasileira de Insuficiência Cardíaca – 2021
Marcondes‐Braga, F. G., Moura, L. Z., Issa, V. S., Vieira, J. L., Rohde, L. E. P., Simões, M. V., Fernandes-Silva, M. M., Rassi, S., Martins, S. M., de Albuquerque, D. C., et al. (2021) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20210367 · Cited by 245
Current and future therapeutic perspective in chronic heart failure
Mascolo, A., di Mauro, G., Cappetta, D., Angelis, A. D., Torella, D., Urbanek, K., Berrino, L., Nicoletti, G. F., Capuano, A., & Rossi, F. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.106035 · Cited by 150
Diabetic cardiomyopathy: Clinical phenotype and practice
Zhao, X., Liu, S., Wang, X., Chen, Y., Pang, P., Yang, Q., Lin, J., Deng, S., Shen-tao, W., Fan, G., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1032268 · Cited by 133
“Patients with chronic HFrEF who received vericiguat had a lower incidence of cardiovascular death or hospitalization for heart failure than those who received placebo (230).”
BackgroundVoors, A. A., Mulder, H. S., Reyes, E. B., Cowie, M., Lassus, J. P. E., Hernandez, A. F., Ezekowitz, J. A., Butler, J., O’Connor, C. M., Koglin, J., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2221 · Cited by 128
Self-citationDetecting structural heart disease from electrocardiograms using AI
Poterucha, T. J., Jing, L., Ricart, R. P., Adjei-Mosi, M., Finer, J., Hartzel, D., Kelsey, C., Long, A., Rocha, D., Ruhl, J. A., et al. (2025) · Nature · doi:10.1038/s41586-025-09227-0 · Cited by 116
Voors, A. A., Tamby, J., Cleland, J. G. F., Koren, M. J., Forgosh, L. B., Gupta, D. K., Lund, L. H., Camacho, A., Karra, R., Swart, H. P., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1933 · Cited by 108
“…i.e. with current or recent heart failure hospitalization and elevated NT-proBNP (populations studied in recently completed VICTORIA trial 32 and in ongoing GALACTIC-HF trial 3 1 ) or advanced heart failure (highly symptomatic, with signs and symptoms of congestion, and refractory to…”
BackgroundSelf-citationPrognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial
Januzzi, J. L., Zannad, F. M., Anker, S. D., Butler, J., Filippatos, G. S., Pocock, S., Ferreira, J. P., Sattar, N. A., Verma, S., Vedin, O., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.07.046 · Cited by 118
Self-citationTargeting Cyclic Guanosine Monophosphate to Treat Heart Failure
Emdin, M., Aimo, A., Castiglione, V., Vergaro, G., Georgiopoulos, G. A., Saccaro, L. F., Lombardi, C., Passino, C., Cerbai, E., Metra, M., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.08.031 · Cited by 112
Metra, M., Adamo, M., Tomasoni, D., Mebazaa, A., Bayés‐Genís, A., Abdelhamid, M., Adamopoulos, S. N., Anker, S. D., Bauersachs, J. K., Belenkov, Y. N., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2888 · Cited by 143
Self-citationSoluble GC stimulators and activators: Past, present and future
Sandner, P., Follmann, M., Becker‐Pelster, E., Hahn, M. G., Meier, C., Freitas, C., Roessig, L., & Stasch, J. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15698 · Cited by 114
Self-citationNitric Oxide Signaling and Regulation in the Cardiovascular System: Recent Advances
Carlström, M., Weitzberg, E., & Lundberg, J. O. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.124.001060 · Cited by 103
Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiac hypertrophy and heart failure
Kamel, R., Leroy, J., Vandecasteele, G., & Fischmeister, R. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00756-z · Cited by 110
Pulmonary hypertension associated with left heart disease
Maron, B. A., Bortman, G., Marco, T. D., Huston, J., Lang, I. M., Rosenkranz, S. L., Vachiéry, J., & Tedford, R. J. (2024) · European Respiratory Journal · doi:10.1183/13993003.01344-2024 · Cited by 125
“…mixed results [54], Since the 6th WSPH, the Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) trial [55] was completed, which randomised 5050 patients with chronic heart failure and LVEF 45% to receive the soluble guanylyl cyclase (sGC) stimulator…”
Calcium and Reactive Oxygen Species Signaling Interplays in Cardiac Physiology and Pathologies
Nicolo, B. D., Cataldi-Stagetti, E., Diquigiovanni, C., & Bonora, E. (2023) · Antioxidants · doi:10.3390/antiox12020353 · Cited by 117
Tromp, J., Ponikowski, P., Salsali, A., Angermann, C. E., Biegus, J., Blatchford, J., Collins, S. P., Ferreira, J. P., Grauer, C., Kosiborod, M., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2137 · Cited by 99
Self-citationO’Brien, C., Ozen, M. O., Ikeda, G., Vaskova, E. A., Jung, J. H., Bayardo, N., Santoso, M. R., Shi, L., Wahlquist, C., Jiang, Z., et al. (2021) · JACC CardioOncology · doi:10.1016/j.jaccao.2021.05.006 · Cited by 108
Savarese, G., Lindberg, F., Cannata, A. N., Chioncel, O. D., Stolfo, D., Musella, F., Tomasoni, D., Abdelhamid, M., Banerjee, D., Bayés‐Genís, A., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3295 · Cited by 114
SGLT2 Inhibitors and Ketone Metabolism in Heart Failure
Saucedo‐Orozco, H., Voorrips, S. N., Yurista, S. R., de Boer, R. A., & Westenbrink, B. D. (2022) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2022.11.1.1 · Cited by 114
Signaling cascades in the failing heart and emerging therapeutic strategies
He, X., Du, T., Long, T., Liao, X., Dong, Y., & Huang, Z. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00972-6 · Cited by 113
“In the VICTORIA trial, vericiguat improved the prognosis of patients with heart failure with reduced ejection fraction.(351) The success of the VICTORIA trial builds confidence in the future exploration of novel medications targeting the NO/cGMP pathway.”
BackgroundButler, J., McMullan, C. J., Anstrom, K. J., Barash, I., Bonaca, M. P., Borentain, M., Corda, S., Ezekowitz, J. A., Felker, G. M., Gates, D. F., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01665-4 · Cited by 121
Self-citationNitric Oxide-cGMP Signaling in Hypertension: Current and Future Options for Pharmacotherapy
Ataabadi, E. A., Golshiri, K., Jüttner, A. A., Krenning, G., Danser, A. H. J., & Roks, A. J. M. (2020) · Hypertension · doi:10.1161/hypertensionaha.120.15856 · Cited by 102
Optimizing Foundational Therapies in Patients With HFrEF
Sharma, A., Verma, S., Bhatt, D. L., Connelly, K. A., Swiggum, E., Vaduganathan, M., Zieroth, S. R., & Butler, J. (2022) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2021.10.018 · Cited by 107
Self-citationvan der Velden, J., Asselbergs, F. W., Bakkers, J., Bátkai, S., Bertrand, L., Bezzina, C. R., Bot, I., Brundel, B. J. J. M., Carrier, L., Chamuleau, S. A. J., et al. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvab370 · Cited by 105
Lam, C. S. P., Giczewska, A., Sliwa, K. S., Edelmann, F., Refsgaard, J. C., Bocchi, E. A., Ezekowitz, J. A., Hernandez, A. F., O’Connor, C. M., Roessig, L., et al. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.6455 · Cited by 89
Self-citationWang, S. Y., Elizondo, J. V., Ali, H., Pandey, A., Cainzos‐Achirica, M., Krumholz, H. M., Nasir, K., & Khera, R. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.121.022164 · Cited by 98
Cyclic GMP and PKG Signaling in Heart Failure
Numata, G., & Takimoto, E. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.792798 · Cited by 105
Amdani, S. M., Conway, J. L., George, K., Martinez, H. R., Asante‐Korang, A., Goldberg, C. S., Davies, R. R., Miyamoto, S. D., & Hsu, D. T. (2024) · Circulation · doi:10.1161/cir.0000000000001245 · Cited by 117
Activation mechanism of human soluble guanylate cyclase by stimulators and activators
Liu, R., Kang, Y., & Chen, L. (2021) · Nature Communications · doi:10.1038/s41467-021-25617-0 · Cited by 98
Tomasoni, D., Vishram‐Nielsen, J. K. K., Pagnesi, M., Adamo, M., Lombardi, C., Gustafsson, F., & Metra, M. (2022) · ESC Heart Failure · doi:10.1002/ehf2.13859 · Cited by 97
Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials
Fiuzat, M., HAMO, C. E., Butler, J., Abraham, W. T., DeFilippis, E. M., Fonarow, G. C., Lindenfeld, J. M., Mentz, R. J., Psotka, M. A., Solomon, S. D., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.11.033 · Cited by 89
Self-citationZandijk, A. J. L., van Norel, M. R., Julius, F. E. C., Sepehrvand, N., Pannu, N., McAlister, F. A., Voors, A. A., & Ezekowitz, J. A. (2021) · JACC Heart Failure · doi:10.1016/j.jchf.2021.07.006 · Cited by 83
Self-citationInhibition of Fap Promotes Cardiac Repair by Stabilizing BNP
Sun, Y., Ma, M., Cao, D., Zheng, A., Zhang, Y., Su, Y., Wang, J., Xu, Y., Zhou, M., Tang, Y., et al. (2023) · Circulation Research · doi:10.1161/circresaha.122.320781 · Cited by 89
Towards precision medicine in heart failure
Weldy, C. S., & Ashley, E. A. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00566-9 · Cited by 89
Contemporary pharmacological treatment and management of heart failure
Bozkurt, B. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-024-00997-0 · Cited by 93
Guía ESC 2021 sobre la prevención de la enfermedad cardiovascular en la práctica clínica
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Bénétos, A., Biffi, A., Boavida, J. M., Capodanno, D., et al. (2022) · Revista Española de Cardiología · doi:10.1016/j.recesp.2021.10.016 · Cited by 123
Natriuretic peptide pathways in heart failure: further therapeutic possibilities
Sangaralingham, S. J., Kühn, M., Cannone, V., Chen, H. H., & Burnett, J. C. J. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac125 · Cited by 88
Implications of Atrial Fibrillation for Guideline-Directed Therapy in Patients With Heart Failure
Newman, J. D., O’Meara, E., Böhm, M., Savarese, G., Kelly, P. R., Vardeny, O., Allen, L. A., Lancellotti, P., Gottlieb, S. S., Samad, Z. Z., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.12.033 · Cited by 96
Secondary Mitral Regurgitation
O’Gara, P. T., & Mack, M. J. (2020) · New England Journal of Medicine · doi:10.1056/nejmcp1903331 · Cited by 86
Markham, A., & Duggan, S. T. (2021) · Drugs · doi:10.1007/s40265-021-01496-z · Cited by 76
“1 Phase III Vericiguat was associated with a lower incidence of death from cardiovascular causes and lower hospitalization for heart failure than placebo in patients with high risk heart failure and reduced ejection fraction participating in the phase III Vericiguat Global Study in Subjects with Heart Failure with Red…”
BackgroundInfluentialHeart Failure in the Last Year: Progress and Perspective
Tomasoni, D., Adamo, M., Anker, M. S., von Haehling, S., Coats, A. J. S., & Metra, M. (2020) · ESC Heart Failure · doi:10.1002/ehf2.13124 · Cited by 100
“02).(197) Baseline characteristics of VIC-”
Böettcher, M., Thomas, D., Mueck, W., Loewen, S., Arens, E. R., Yoshikawa, K., & Becker, C. (2020) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-020-03023-7 · Cited by 72
Blood Pressure and Safety Events With Vericiguat in the VICTORIA Trial
Lam, C. S. P., Mulder, H., Lopatin, Y., Vazquez‐Tanus, J. B., Siu, D., Ezekowitz, J. A., Pieske, B. M., O’Connor, C. M., Roessig, L., Patel, M. J., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.121.021094 · Cited by 73
Self-citationAimo, A., Pateras, K., Stamatelopoulos, K. S., Bayés‐Genís, A., Lombardi, C., Passino, C., Emdin, M., & Georgiopoulos, G. A. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07099-2 · Cited by 74
Guideline-Directed Medical Therapy for the Treatment of Heart Failure with Reduced Ejection Fraction
Patel, J., Rassekh, N., Fonarow, G. C., DEEDWANIA, P. C., Sheikh, F. H., Ahmed, A., & Lam, P. H. (2023) · Drugs · doi:10.1007/s40265-023-01887-4 · Cited by 89
“The VICTORIA trial demonstrated that the addition of vericiguat to maximally tolerated GDMT resulted in a lower primary composite outcome of cardiovascular death or heart failure hospitalization, with the modest outcome driven by a reduction in heart failure hospitalization [59].”
MethodSolomon, S. D., Ostrominski, J. W., Vaduganathan, M., Claggett, B. L., Jhund, P. S., Desai, A. S., Lam, C. S. P., Pitt, B., Senni, M., Shah, S. J., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3266 · Cited by 78
Self-citationMechanisms and Models in Heart Failure: A Translational Approach
Mann, D. L., & Felker, G. M. (2021) · Circulation Research · doi:10.1161/circresaha.121.318158 · Cited by 84
Mitochondrial dysfunction in heart failure and its therapeutic implications
Liu, M., Lv, J., Pan, Z., Wang, D., Zhao, L., & Guo, X. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.945142 · Cited by 83
“Although recent evidence showed cardiac myosin activator Omecamtiv Mecarbil (117) and the soluble guanylate cyclase stimulator Vericiguat (118) can benefit patients with heart failure, the outcome of heart failure especially HFpEF is still difficult to change fundamentally.”
BackgroundTeerlink, J. R., Díaz, R., Felker, G. M., McMurray, J. J. V., Metra, M., Solomon, S. D., Adams, K. F., Anand, I. S., Arias‐Mendoza, A., Biering‐Sørensen, T., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.2015 · Cited by 68
Self-citationSex-Specific Differences in Heart Failure: Pathophysiology, Risk Factors, Management, and Outcomes
Sullivan, K., Doumouras, B. S., Santema, B. T., Walsh, M. N., Douglas, P. S., Voors, A. A., & Spall, H. G. C. V. (2020) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2020.12.025 · Cited by 72
Self-citationPerego, C., Sbolli, M., Specchia, C., Fiuzat, M., McCaw, Z. R., Metra, M., Oriecuia, C., Peveri, G., Wei, L., O’Connor, C. M., et al. (2020) · JACC Heart Failure · doi:10.1016/j.jchf.2020.07.005 · Cited by 76
Self-citationLewis, G. D., Voors, A. A., Solal, A. C., Metra, M., Whellan, D. J., Ezekowitz, J. A., Böhm, M., Teerlink, J. R., Docherty, K. F., Lópes, R. D., et al. (2022) · JAMA · doi:10.1001/jama.2022.11016 · Cited by 76
Self-citationSacubitril/Valsartan in Patients With Heart Failure and Concomitant End‐Stage Kidney Disease
Niu, C., Yang, S., Ou, S., Wu, C., Huang, P., Hung, C., Lin, C., & Li, S. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.122.026407 · Cited by 70
Current and emerging drug targets in heart failure treatment
Ghionzoli, N., Gentile, F., Franco, A. D., Castiglione, V., Aimo, A., Giannoni, A., Burchielli, S., Cameli, M., Emdin, M., & Vergaro, G. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10137-2 · Cited by 72
Similarities and Differences Between HFmrEF and HFpEF
Li, P., Zhao, H., Zhang, J., Ning, Y., Tu, Y., Xu, D., & Zeng, Q. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.678614 · Cited by 75
Recent successes in heart failure treatment
Lam, C. S. P., Docherty, K. F., Ho, J. E., McMurray, J. J. V., Myhre, P. L., & Omland, T. (2023) · Nature Medicine · doi:10.1038/s41591-023-02567-2 · Cited by 71
“In the prior VICTORIA trial, vericiguat had a modest clinical benefit in a higher-risk population of patients with a LVEF 45%, markedly elevated natriuretic peptides and recent worsening of HF (usually resulting in hospitalization) 99 .”
MethodSelf-citationSenni, M., López-Sendón, J., Solal, A. C., Ponikowski, P. P., Nkulikiyinka, R., Freitas, C., Vlajnic, V., Roessig, L., & Pieske, B. M. (2022) · ESC Heart Failure · doi:10.1002/ehf2.14050 · Cited by 65
“Of note, a prognostic model developed using the VICTORIA dataset that included these factors as covariates did not identify any evidence of treatment modification stronger than that observed with baseline NT-proBNP.(2,3) The higher rates of the primary outcome and its components, as well as all-cause deaths in Q4 comp…”
BackgroundMethodSelf-citationHeart Failure: An Update from the Last Years and a Look at the Near Future
Riccardi, M., Sammartino, A. M., Piepoli, M. F., Adamo, M., Pagnesi, M., Rosano, G. M. C., Metra, M., von Haehling, S., & Tomasoni, D. (2022) · ESC Heart Failure · doi:10.1002/ehf2.14257 · Cited by 81
“and recently decompensated HF.(140,141) Benefits were consis-”
Metadata
- Authors
- Armstrong, P. W., Pieske, B., Anstrom, K. J., Ezekowitz, J., Hernandez, A. F., Butler, J., Lam, C. S. P., Ponikowski, P., Voors, A. A., Jia, G., McNulty, S. E., Patel, M. J., Roessig, L., Koglin, J., & O’Connor, C. M.
- Affiliations
- University of Alberta (CA)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Inova Health System (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-05-14
- Volume
- 382
- Issue
- 20
- Pages
- 1883-1893
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3013207865
- Semantic Scholar
- f98a684f8b44644864e75febeca130b492e75a2c
- Cited by
- 1,358
- References
- 17
- Citations by year
- 2026: 170 · 2025: 213 · 2024: 189 · 2023: 253 · 2022: 225 · 2021: 207 · 2020: 96
- FWCI
- 121.19
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- HAL (submittedVersion)
- Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Bayer
- Merck
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Keywords
- vericiguat, heart failure with reduced ejection fraction, soluble guanylate cyclase stimulator, cardiovascular mortality, heart failure hospitalization, symptomatic hypotension, syncope, chronic heart failure
- MeSH terms
- Soluble Guanylyl Cyclase, Administration, Oral, Aged, Cardiovascular Diseases, Chronic Disease, Double-Blind Method, Female, Follow-Up Studies, Heart Failure, Heterocyclic Compounds, 2-Ring, Hospitalization, Humans, Hypotension, Male, Middle Aged, Pyrimidines, Stroke Volume, Syncope, Incidence, Ventricular Dysfunction, Left
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.